Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis

New findings presented at ATS 2021 Conference also suggest novel test can be successfully enabled on nCounter Analysis System to support international expansion

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced that data reinforcing the diagnostic performance and utility of the Envisia® Genomic Classifier are being shared at the American Thoracic Society (ATS) 2021 International Conference, taking place today through May 18. The company is also presenting new data which demonstrate that the novel genomic test can be successfully enabled on the nCounter Analysis System, supporting the company’s plans to make the novel test – for improved diagnosis of interstitial lung diseases (ILDs) – available to physicians and their patients in global markets.

Each year in the United States and Europe, up to 220,000 patients are evaluated for suspected ILDs, including idiopathic pulmonary fibrosis (IPF), which is among the most common, deadly and difficult to diagnose of these lung-scarring diseases. The Envisia Genomic Classifier detects a genomic pattern of usual interstitial pneumonia (UIP) to improve ILD diagnostic and prognostic confidence. The test is performed in Veracyte’s U.S.-based CLIA laboratory. The company plans to be ready to make the Envisia classifier available on the nCounter Analysis System in international markets by the end of this year, which will enable laboratories to perform the test locally.

In one Envisia-related poster presented today, researchers assessed the classifier’s ability to detect UIP among a subset of ILD patients with clinical characteristics that are less commonly associated with IPF (